IDEAYA Completes Enrollment of 435 Patients for Darovasertib Trial, Supporting Approval Filing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy IDYA?
Source: Newsfilter
- Enrollment Completion: IDEAYA has successfully enrolled 435 patients in the OptimUM-02 trial, laying the groundwork for a potential full approval filing for darovasertib, highlighting the drug's significance in treating metastatic uveal melanoma.
- Data Expectations: Median progression-free survival (PFS) data is expected to be reported in Q1 2026, which will support an accelerated approval filing in the U.S., further advancing the company's strategic positioning in precision medicine.
- Clinical Potential: The combination of darovasertib and crizotinib demonstrated a median overall survival (OS) of 21.1 months in previous trials, indicating its clinical potential to significantly improve patient outcomes in metastatic uveal melanoma.
- Regulatory Support: Darovasertib has received FDA Breakthrough Therapy and Orphan Drug Designations, underscoring its importance in treating metastatic uveal melanoma and enhancing IDEAYA's competitive edge in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 31.520
Low
30.00
Averages
49.86
High
79.00
Current: 31.520
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences to Participate in Investor Events
- Investor Event Schedule: IDEAYA Biosciences will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, showcasing its latest advancements in precision medicine oncology, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Fireside Chat: The company will also host a virtual fireside chat on February 23, 2026, led by Umer Raffat of Evercore ISI, aimed at discussing its product candidates and R&D strategies in depth, further enhancing investor engagement.
- Webcast Availability: Live audio of the events will be available on IDEAYA's website under the
See More
IDEAYA Biosciences to Participate in Investor Events
- Investor Event Schedule: IDEAYA Biosciences will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, featuring a fireside chat with executives including Chief Medical Officer Darrin Beaupre, which is expected to enhance the company's visibility among investors.
- Interactive Online Opportunities: The company will also host a virtual fireside chat on February 23, 2026, with CEO Yujiro S. Hata and other executives discussing their leadership in precision medicine, further solidifying their market position.
- Live Webcast and Replay: All events will be available via live audio webcast on IDEAYA's website under the
See More
IDEAYA Grants 44,200 Stock Options to New Employee
- Options Grant Overview: On January 29, 2026, IDEAYA Biosciences granted 44,200 non-qualified stock options to a new employee, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Details: The stock options have an exercise price of $32.99 per share, matching the closing price of IDEAYA's common stock on the grant date, thereby aligning employee interests with company performance.
- Vesting Schedule: The options have a 10-year term with a four-year vesting period, where 25% vests on the first anniversary and the remaining 75% vests in equal monthly installments over the next three years, incentivizing long-term employee retention and contribution.
- Strategic Focus: IDEAYA is committed to precision medicine and oncology, focusing on developing transformative therapies for cancer by integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
IDEAYA Grants 44,200 Stock Options to New Employee
- Options Grant: On January 29, 2026, IDEAYA granted 44,200 non-qualified stock options to a new employee, aimed at attracting top talent to the company in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were granted under the 2023 Employment Inducement Incentive Award Plan, specifically designed for individuals who were not previously employed by IDEAYA, reflecting the company's commitment to new hires.
- Exercise Price: The stock options have an exercise price of $32.99 per share, equal to the closing price of IDEAYA's common stock on the grant date on the Nasdaq Global Select Market, ensuring employees receive fair market value.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the next three years, ensuring continued employee service to IDEAYA for incentive eligibility.
See More
IDEAYA Biosciences Updates 2026 Corporate Objectives at J.P. Morgan Conference
- Pipeline Advancement: In 2025, IDEAYA successfully advanced multiple clinical projects, filing four INDs resulting in nine clinical programs, demonstrating the company's strong execution and readiness in the precision medicine oncology sector.
- Key Trial Plans: In 2026, IDEAYA plans to advance four registrational trials, including IDE849 as a monotherapy for neuroendocrine cancer and darovasertib for both pre-metastatic and metastatic uveal melanoma, aiming to improve patient prognosis and quality of life.
- Funding Assurance: The company expects its cash runway to support operations into 2030, ensuring the continued advancement of key combination therapies in high unmet need cancer areas, thereby enhancing its market competitiveness.
- Strategic Vision: IDEAYA is committed to developing targeted cancer therapies, particularly in the uveal melanoma space where FDA-approved treatments are lacking, showcasing its leadership and innovative potential in precision oncology.
See More
IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials
- Advancement of Registrational Trials: IDEAYA plans to advance four registrational trials in 2026, including darovasertib for uveal melanoma, aimed at improving patient prognosis and addressing the lack of FDA-approved therapies.
- Clinical Data Release: Topline PFS data from the darovasertib and crizotinib combination is expected in Q1 2026, and if positive, will support a potential accelerated approval filing in the U.S., enhancing market competitiveness.
- Financial Assurance: As of September 30, 2025, IDEAYA has approximately $1.1 billion in cash and cash equivalents, expected to fund its operating plan into 2030, ensuring ongoing investment in R&D.
- New Drug Development: The company plans to initiate a registrational study for IDE849 targeting small cell lung cancer and neuroendocrine carcinomas by the end of 2026, showcasing its ongoing innovation in precision medicine.
See More
IDEAYA Biosciences to Participate in Investor Events
- Investor Event Schedule: IDEAYA Biosciences will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, showcasing its latest advancements in precision medicine oncology, which is expected to attract investor interest and enhance the company's visibility.
- Virtual Fireside Chat: The company will also host a virtual fireside chat on February 23, 2026, led by Umer Raffat of Evercore ISI, aimed at discussing its product candidates and R&D strategies in depth, further enhancing investor engagement.
- Webcast Availability: Live audio of the events will be available on IDEAYA's website under the
See More
IDEAYA Biosciences to Participate in Investor Events
- Investor Event Schedule: IDEAYA Biosciences will participate in Citi's 2026 Virtual Oncology Leadership Summit on February 18, 2026, featuring a fireside chat with executives including Chief Medical Officer Darrin Beaupre, which is expected to enhance the company's visibility among investors.
- Interactive Online Opportunities: The company will also host a virtual fireside chat on February 23, 2026, with CEO Yujiro S. Hata and other executives discussing their leadership in precision medicine, further solidifying their market position.
- Live Webcast and Replay: All events will be available via live audio webcast on IDEAYA's website under the
See More
IDEAYA Grants 44,200 Stock Options to New Employee
- Options Grant Overview: On January 29, 2026, IDEAYA Biosciences granted 44,200 non-qualified stock options to a new employee, aimed at attracting top talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Exercise Price Details: The stock options have an exercise price of $32.99 per share, matching the closing price of IDEAYA's common stock on the grant date, thereby aligning employee interests with company performance.
- Vesting Schedule: The options have a 10-year term with a four-year vesting period, where 25% vests on the first anniversary and the remaining 75% vests in equal monthly installments over the next three years, incentivizing long-term employee retention and contribution.
- Strategic Focus: IDEAYA is committed to precision medicine and oncology, focusing on developing transformative therapies for cancer by integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to advance personalized treatment options.
See More
IDEAYA Grants 44,200 Stock Options to New Employee
- Options Grant: On January 29, 2026, IDEAYA granted 44,200 non-qualified stock options to a new employee, aimed at attracting top talent to the company in accordance with Nasdaq Listing Rule 5635(c)(4).
- Incentive Plan Context: The stock options were granted under the 2023 Employment Inducement Incentive Award Plan, specifically designed for individuals who were not previously employed by IDEAYA, reflecting the company's commitment to new hires.
- Exercise Price: The stock options have an exercise price of $32.99 per share, equal to the closing price of IDEAYA's common stock on the grant date on the Nasdaq Global Select Market, ensuring employees receive fair market value.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the next three years, ensuring continued employee service to IDEAYA for incentive eligibility.
See More
IDEAYA Biosciences Updates 2026 Corporate Objectives at J.P. Morgan Conference
- Pipeline Advancement: In 2025, IDEAYA successfully advanced multiple clinical projects, filing four INDs resulting in nine clinical programs, demonstrating the company's strong execution and readiness in the precision medicine oncology sector.
- Key Trial Plans: In 2026, IDEAYA plans to advance four registrational trials, including IDE849 as a monotherapy for neuroendocrine cancer and darovasertib for both pre-metastatic and metastatic uveal melanoma, aiming to improve patient prognosis and quality of life.
- Funding Assurance: The company expects its cash runway to support operations into 2030, ensuring the continued advancement of key combination therapies in high unmet need cancer areas, thereby enhancing its market competitiveness.
- Strategic Vision: IDEAYA is committed to developing targeted cancer therapies, particularly in the uveal melanoma space where FDA-approved treatments are lacking, showcasing its leadership and innovative potential in precision oncology.
See More
IDEAYA Biosciences Updates 2026 Strategic Objectives, Plans to Advance Four Registrational Trials
- Advancement of Registrational Trials: IDEAYA plans to advance four registrational trials in 2026, including darovasertib for uveal melanoma, aimed at improving patient prognosis and addressing the lack of FDA-approved therapies.
- Clinical Data Release: Topline PFS data from the darovasertib and crizotinib combination is expected in Q1 2026, and if positive, will support a potential accelerated approval filing in the U.S., enhancing market competitiveness.
- Financial Assurance: As of September 30, 2025, IDEAYA has approximately $1.1 billion in cash and cash equivalents, expected to fund its operating plan into 2030, ensuring ongoing investment in R&D.
- New Drug Development: The company plans to initiate a registrational study for IDE849 targeting small cell lung cancer and neuroendocrine carcinomas by the end of 2026, showcasing its ongoing innovation in precision medicine.
See More
